Nov 11 (Reuters) - Zalicus Inc said it would stopdeveloping an experimental pain drug after it failed to show abenefit over a placebo in two mid-stage trials.
The drug, called Z160, was being developed for treatingchronic pain. Zalicus said it now planned to focus on anotherpain drug, Z944.
The company's shares were halted in pre-market trading. Theyclosed at $4.69 on Friday on the Nasdaq.
- Health Care Industry
- Pharmaceuticals & Drug Trials
- chronic pain